STOCK TITAN

Shattuck Labs, Inc. - STTK STOCK NEWS

Welcome to our dedicated page for Shattuck Labs news (Ticker: STTK), a resource for investors and traders seeking the latest updates and insights on Shattuck Labs stock.

Introduction

Shattuck Labs, Inc. is a clinical-stage biotechnology company that is pioneering the development of dual-action fusion proteins, a new class of biologic medicines. Utilizing their proprietary Agonist Redirected Checkpoint (ARC®) platform, the company is dedicated to designing bi-functional fusion proteins capable of simultaneously inhibiting immune checkpoints and activating costimulatory pathways. This approach is instrumental in reactivating anti-tumor immune responses and modulating autoimmune mechanisms, addressing significant unmet needs in oncology and autoimmune disorders.

Innovative Technology and Platform

The core of Shattuck Labs’ innovation lies in its proprietary ARC® platform, which enables the rational design of fusion proteins with a dual mechanism of action. By targeting key immune checkpoints such as CD47 and PD-1 while concurrently stimulating costimulatory receptors like CD40 and OX40, the company is able to enhance the efficacy of immune-mediated treatments without the need for multiple separate therapies. This strategic integration of inhibitory and agonistic functions within a single molecule sets the company apart in the competitive biotechnology landscape.

Product Pipeline and Clinical Programs

Shattuck Labs is actively advancing several clinical programs with its innovative fusion protein candidates:

  • SL-172154 (SIRPα-Fc-CD40L): Designed to block inhibitory checkpoints and stimulate immune activation, this candidate is undergoing early-phase clinical evaluation to address advanced cancer indications.
  • SL-279252 (PD1-Fc-OX40L): Developed in collaboration with a major pharmaceutical partner, this compound exemplifies the company’s commitment to designing fusion proteins that combine checkpoint inhibition with costimulatory activation.
  • Gamma Delta T Cell Engager Platform: Known as gadlen™, this innovative approach aims to bridge gamma delta T cells to tumor antigens, thereby enhancing the immune system’s ability to target and destroy cancer cells.

Throughout these programs, Shattuck Labs maintains a balanced focus on therapeutic innovation, clinical safety, and efficacy, which is thoroughly reflected in their robust preclinical data and ongoing Phase 1 clinical studies.

Market Position and Competitive Landscape

In the dynamic field of biotechnology, Shattuck Labs has carved out a unique niche by leveraging advanced protein engineering and novel therapeutic strategies. The company’s dual-action approach not only positions it as an innovator in the development of biologic medicines but also enables it to address complex diseases with limited treatment options. With clinical programs targeting both hematologic malignancies and autoimmune conditions, Shattuck Labs stands as a significant contributor in the realm of precision immunotherapy and therapeutic innovation.

Expertise, Experience, and Corporate Profile

With offices located in Austin, Texas and Durham, North Carolina, Shattuck Labs benefits from a strong foundation in regional biotech hubs known for their robust research and development ecosystems. The company’s leadership and scientific teams bring extensive expertise in protein engineering, immuno-oncology, and drug development. Their work not only reflects a deep understanding of molecular biology and immune regulation but also underscores a disciplined approach to clinical development that is critical for advancing novel therapeutics safely and effectively.

Understanding the Bi-Functional Fusion Protein Approach

At the heart of Shattuck Labs’ operations is the concept of a bi-functional fusion protein – a therapeutic designed to perform two critical functions within one molecule. This innovative approach allows for:

  • Simultaneous inactivation of inhibitory checkpoints that normally prevent an effective immune response.
  • Activation of costimulatory pathways that enhance the body's ability to combat cancer cells or manage autoimmune responses.

This dual mechanism is a testament to the company’s expertise in synthesizing complex biological data and leveraging cutting-edge protein design to create more potent therapies with a potentially improved safety profile.

Conclusion

Shattuck Labs, Inc. represents a forward-thinking force in the biotechnology industry. By integrating innovative dual-action fusion proteins with state-of-the-art research and a well-structured clinical development program, the company continues to bolster its position as an informed and experienced player in the field of biologic medicine. Investors and industry stakeholders will find that the company not only addresses pressing medical challenges but also exemplifies a commitment to scientific rigor and therapeutic innovation.

Rhea-AI Summary
Shattuck Labs, Inc. (STTK) reports positive interim data from Phase 1B clinical trials of SL-172154 in treating ovarian cancer and acute myeloid leukemia. The company also provided financial results for Q3 2023, showing cash and cash equivalents of $101.1 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-23.21%
Tags
-
Rhea-AI Summary
Shattuck Labs, a clinical-stage biotechnology company, will report its third-quarter 2023 financial results and provide a general business overview on November 9, 2023. The earnings call will feature CEO Taylor Schreiber, CFO Andrew Neill, and CMO Lini Pandite. Interested participants can join the webcast or dial in using the provided details. A replay of the webcast will be available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.05%
Tags
conferences earnings
-
Rhea-AI Summary
Shattuck Labs, Inc. announced topline data from the Phase 1 A/B clinical trial of SL-172154 in patients with AML and HR-MDS. The data showed anti-leukemic activity and a tolerable safety profile for SL-172154 as monotherapy and in combination with azacitidine. Response rates were observed in heavily pretreated patients, and early efficacy signals were seen in previously untreated patients with TP53 mutant HR-MDS. The abstract and additional details can be accessed on the ASH Congress portal.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.5%
Tags
conferences clinical trial
Rhea-AI Summary
Shattuck Labs, Inc. presented data from Phase 1A clinical trial of SL-172154 in ovarian cancer. Enrollment progressing in Phase 1B trials in AML and PROC. Financial results show cash and investments of $117.2 million as of June 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.25%
Tags
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.11%
Tags
Rhea-AI Summary

Shattuck Labs, Inc. (NASDAQ: STTK), a clinical-stage biotech firm, announced its participation in the 22nd Annual Needham Virtual Healthcare Conference from April 17-20, 2023. The fireside chat will be held on April 19, 2023, featuring CEO Taylor Schreiber and CFO Andrew Neill, from 2:15 to 2:55 p.m. ET. The discussion will be available via live webcast and archived for 90 days. Shattuck is focused on developing bi-functional fusion proteins for treating cancer and autoimmune diseases, leveraging its proprietary ARC® platform and the SL-172154 program, currently in multiple Phase 1 trials.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.04%
Tags
none
-
Rhea-AI Summary

The press release from Shattuck Labs (NASDAQ: STTK) highlights preclinical findings from the GADLEN platform presented at the AACR Annual Meeting. The CD20-targeted GADLEN demonstrated a rapid and efficient ability to deplete over 99% of human B cells in humanized mouse models and non-human primates without significant toxic effects. This promising data suggests potential for treating antibody-mediated autoimmune diseases. The GADLEN compound was well-tolerated at doses up to 25 mg/kg, indicating a favorable safety profile compared to existing T cell engagers.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.93%
Tags
-
Rhea-AI Summary

Shattuck Labs, Inc. (NASDAQ: STTK) announced participation in two key investor conferences in March 2023. The Cowen 43rd Annual Health Care Conference will feature Dr. Lini Pandite discussing innovative oncology approaches on March 6 at 9:10 a.m. ET. On March 13, Dr. Taylor Schreiber will present a corporate overview at the Oppenheimer 33rd Annual Healthcare Conference at 2:00 p.m. ET. Both events will be live-streamed and later archived on the company's website. Shattuck Labs is focused on advancing bi-functional fusion proteins targeting cancer and autoimmune diseases, with several ongoing Phase 1 trials, including its lead program SL-172154.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.6%
Tags
none
Rhea-AI Summary

Shattuck Labs reported significant progress in clinical trials and announced key management changes. The Phase 1B trial of SL-172154 with mirvetuximab soravtansine in platinum-resistant ovarian cancer has begun enrollment. Initial data from this trial and others involving SL-172154 is expected in mid to late 2023. However, the company discontinued the SL-279252 program after failing to meet efficacy thresholds in Phase 1 trials. Financially, Shattuck reported a net loss of $25.4 million for Q4 2022, compared to a net income of $7.8 million a year prior, with R&D expenses rising to $82.9 million for the year. The company forecasts its cash reserves will sustain operations into H2 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.44%
Tags

FAQ

What is the current stock price of Shattuck Labs (STTK)?

The current stock price of Shattuck Labs (STTK) is $0.8459 as of April 1, 2025.

What is the market cap of Shattuck Labs (STTK)?

The market cap of Shattuck Labs (STTK) is approximately 42.5M.

What is the core focus of Shattuck Labs, Inc.?

Shattuck Labs, Inc. is dedicated to the development of bi-functional fusion proteins as a new class of biologic medicine targeting cancer and autoimmune diseases. Its research is centered around a proprietary platform that integrates checkpoint inhibition and receptor activation.

How does the ARC® platform work?

The ARC® platform enables the creation of fusion proteins that simultaneously block inhibitory immune checkpoints and activate costimulatory receptors. This dual-action approach is designed to re-engage the immune system to combat disease more effectively.

Which therapeutic areas does Shattuck Labs target?

The company focuses on treating conditions with high unmet medical needs, notably cancers and autoimmune diseases. Its innovative candidates are in early-phase clinical trials addressing various oncology and immune-related disorders.

What distinguishes Shattuck Labs from other biotech companies?

Shattuck Labs stands out through its unique dual-action fusion protein approach and its proprietary protein engineering capabilities. This strategy allows for the integration of inhibitory and stimulatory functions into a single therapeutic molecule.

Can you elaborate on the company’s product pipeline?

Shattuck Labs’ pipeline includes candidates like SL-172154 and SL-279252, which are designed to modulate immune checkpoints and costimulatory receptors. Additionally, they are advancing innovative platforms such as their gamma delta T cell engager, which further underline their commitment to therapeutic innovation.

Does Shattuck Labs collaborate with other companies?

Yes, Shattuck Labs has established collaborations with major pharmaceutical partners to co-develop innovative therapies. These partnerships help enhance their clinical development strategies and broaden the scope of their therapeutic offerings.
Shattuck Labs, Inc.

Nasdaq:STTK

STTK Rankings

STTK Stock Data

42.46M
41.01M
14.3%
65.38%
3.54%
Biotechnology
Pharmaceutical Preparations
Link
United States
AUSTIN